Home > Drugs A – Z > Palivizumab (By injection)

Palivizumab (By injection)

Prevents infections caused by respiratory syncytial virus (RSV).

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Palivizumab injection is used to prevent serious lung infection in children and babies caused by respiratory syncytial virus (RSV). It belongs to a group of medicines known as immunizing agents. This medicine works by giving your body antibodies to protect it against RSV infection. RSV infection can cause serious problems that affect the lungs, such as pneumonia and bronchitis, and in severe… Read more
Brand names include
Synagis
Drug classes About this
Antiviral, Immunological Agent

What works? Research summarized

Evidence reviews

Palivizumab vaccine for prevention of respiratory syncytial virus infection in children with cystic fibrosis

We reviewed the evidence about the effects of vaccinating children with cystic fibrosis with palivizumab to prevent respiratory syncytial virus.

Palivizumab for reducing the risk of severe RSV infection in children

Respiratory syncytial virus (RSV) infection is a major cause of acute respiratory infections in children. RSV infection can lead to morbidity and mortality in children, resulting in hospitalization, admission to an intensive care unit, the need for intensive medical therapies and death.

Palivizumab for Immunoprophylaxis of Respiratory Syncytial Virus (RSV) Bronchiolitis in High-Risk Infants and Young Children: Systematic Review and Additional Economic Modelling of Subgroup Analyses

Respiratory syncytial virus (RSV) is a seasonal infectious disease, with epidemics occurring annually from October to March in the UK. It is a very common infection in infants and young children and can lead to hospitalisation, particularly in those who are premature or who have chronic lung disease (CLD) or congenital heart disease (CHD). Palivizumab (Synagis®, MedImmune) is a monoclonal antibody designed to provide passive immunity against RSV and thereby prevent or reduce the severity of RSV infection. It is licensed for the prevention of serious lower respiratory tract infection caused by RSV in children at high risk. While it is recognised that a policy of using palivizumab for all children who meet the licensed indication does not meet conventional UK standards of cost-effectiveness, most clinicians feel that its use is justified in some children.

See all (13)

Summaries for consumers

Palivizumab vaccine for prevention of respiratory syncytial virus infection in children with cystic fibrosis

We reviewed the evidence about the effects of vaccinating children with cystic fibrosis with palivizumab to prevent respiratory syncytial virus.

Palivizumab for reducing the risk of severe RSV infection in children

Respiratory syncytial virus (RSV) infection is a major cause of acute respiratory infections in children. RSV infection can lead to morbidity and mortality in children, resulting in hospitalization, admission to an intensive care unit, the need for intensive medical therapies and death.

PubMed Health Blog...

read all...